會員登入
註冊
Taiwan's Cell Therapy: 20 Years of Progress - Reviewing Current Clinical Trials
2023-12-01 / GlobalBio & Investment
Taiwan'sCellTherapy:20YearsofProgress-ReviewingCurrentClinicalTrials Themuch-debatedRegenerativeMedicineActhasbeenthesubjectofongoingdiscussionsformanyyears.Thoughithasconsolidatedfromthreedraftgu...
Taiwan Takes on Global Competition in National Genome Sequencing!
2023-12-01 / GlobalBio & Investment
【Editor'sChoice|GenomeSequencing】TaiwanTakesonGlobalCompetitioninNationalGenomeSequencing!ExpertsUrgeGovernmenttoLeadinLarge-ScaleGenomeSequencingProgram. In1992,theHumanGenomeProjectwaslaunched,a...
Rebuilding Psychological Safety After Drug Allergy: A 4-Step Approach
2023-12-01 / GlobalBio & Investment
RebuildingPsychologicalSafetyAfterDrugAllergy:A4-StepApproachAdrugallergyoccurswhentheimmunesystemreactstoanonprescription,prescription,orherbalmedicine.Patientssufferingfromdrugallergiesexperiencevar...
Hospitals in Taiwan use digital technology to implement medical care
2023-12-01 / GlobalBio & Investment
【Editor'sChoice|Taiwan’sMedicalDevice】Shortenunhealthylifeyears!HospitalsinTaiwanusedigitaltechnologytoimplementmedicalcare TheaveragelifeexpectancyofTaiwanesepeoplehasexceeded80years,butthe...
The Winners of 2023 Best Bio CEO Award held by Globalbio have been revealed!
2023-12-01 / GlobalBio & Investment
TheWinnersof2023BestBioCEOAwardheldbyGlobalbiohavebeenrevealed!Thisyearwehave CytoArm｜Armed-Tcelltherapy, LeadgeneBiomedical,Inc.,and SunWayBiotechCo.,LTD. winningtheawards.Thefirstwinner,CytoArm,feat...
AI Revolutionizing Biomedicine: Recent Advances and Healthcare Applications
2023-12-01 / GlobalBio & Investment
AIRevolutionizingBiomedicine:RecentAdvancesandHealthcareApplicationsAIanditsgenerativecapabilitieshavegainedsignificantattention,particularlyinthefieldofbiomedicine,sinceChatGPT'srisetoprominencei...
76-year-old CSD Successfully Transitions to B2C with Innovative 'Health in Style' Products.
2023-12-01 / GlobalBio & Investment
【Editor'sChoice|Taiwan'sMedicalDevice】76-year-old #CSD SuccessfullyTransitionstoB2CwithInnovative'HealthinStyle'Products. CSD,aleadingbrandinTaiwanforhealthprotectionsupplieswitha76-ye...
Dr. Frank Kung of Vivo Capital Shares US Biotech Trends
2023-12-01 / GlobalBio & Investment
Dr.FrankKungofVivoCapitalSharesUSBiotechTrends:WeaknessContinuesAfter2021Peak,BigPharmaSeeksM&A,IntenseOncology&RareDiseaseCompetitionDr.FrankKung,co-founderandexecutivedirectorofVivoCapitalre...
Next Step: Targeting Neurological Disorders and Cancer Treatment?!
2023-12-01 / GlobalBio & Investment
【Editor'sChoice|Storiesbehind #BIO2023】ModernaCo-founderandAlnylamSeniorVicePresident:WitnessingthePotentialofNucleicAcidTherapyinthePandemic!NextStep:TargetingNeurologicalDisordersandCancerTreatm...
Genomics Raises 4.88 Million in Seasoned Equity Offering
2023-12-01 / GlobalBio & Investment
【Editor'sChoice|GenomeSequencing】UpgradedManufacturingProcessesforDomesticNucleicAcidandPeptide!GenomicsRaises4.88MillioninSeasonedEquityOffering GenomicsBioSci&Tech(4195.TWO)recentlyannounced...
增大原廠挑戰！百靈佳高濃度版Humira生物相似藥 獲FDA可互換批准
2024-05-03 / 實習記者 鐘御慈
昨(2)日，百靈佳殷格翰(BoehringerIngelheim)的高濃度、無檸檬酸鹽藥物配方抗風濕藥物Cyltezo(adalimumab-adbm)，獲美國食品藥物管理局(FDA)批准，該藥物與艾伯維(AbbVie)的重磅抗風濕藥物Humira(adalimumab)為可互換的生物相似藥。Cyltezo的高濃度藥物配方，含有100mg/mL劑量的Cyltezo，且採用預填充式注射器和自動注射器...
美最新乳癌預防指引：40歲以上女性應每兩年一次乳房X光檢查
2024-05-06 / 記者 巫芝岳
近日(4月30日)，美國預防服務工作組(USPSTF)，在醫學期刊《JAMA》中正式發布其最新的乳癌預防指引，建議40~74歲的女性，應每兩年接受一次乳房X光攝影檢查。而根據台灣國健署目前的資訊，政府補助國內45~70歲女性每兩年一次乳房X光攝影檢查；40~45歲具有乳癌家族史的女性則為每兩年一次。根據USPSTF最新建議，由於美國40多歲女性的乳癌罹患率，正以每年增加2%的速率成長中，因此提出本...
